|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results showed that TAP7f inhibited melanoma cell proliferation in vivo, as determined by a decreased expression of proliferating cell nuclear antigen, inducing a significant reduction of tumor growth.
|
29494356 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
|
24289491 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have investigated the potential for the p16-cyclin D-CDK4/6-retinoblastoma protein pathway to be exploited as a therapeutic target in melanoma.
|
24495407 |
2014 |
|
melanoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
It causes growth arrest in melanocytes, associated with the inhibition of Cyclin E/Cdk2 and β-catenin phosphorylation at the transcriptional activity site Ser(552) and is silenced through DNA methylation in 27/35 (77%) melanoma tissues/early cultures.
|
21649464 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This analysis highlighted proliferating cell nuclear antigen and survivin as priorities for further examination as biomarkers in melanoma prognosis, and illustrated ongoing need to integrate alternative approaches to biomarker discovery in melanoma translational research.
|
21659462 |
2011 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Selective expression of progesterone receptor in malignant melanoma was inversely correlated with PCNA.
|
18481002 |
2008 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Deregulation of melanoma cell growth has been widely associated with mutations in the p16-cyclin D/cdk4-pRb pathway.
|
17218782 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Expression of peripheral benzodiazepine receptor, PCNA, and caspase-3 in cells of skin melanoma and squamous cell carcinoma.
|
18256758 |
2007 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The mean score of PCNA and Ki-67 index were the highest in tumours, which contained epithelioid cells and in large, more advanced (pT3, pT4) uveal melanomas.
|
15638382 |
2004 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cyclin E, p21(Waf-1) and p27(Kip-1) are also elevated in many primary melanomas, whereas p16(INK4a) is mutated or deleted in many invasive and metastatic melanomas.
|
11602203 |
2001 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data strongly support the idea that deregulation of the CDK4/cyclin D pathway, via CDKN2 or CDK4 mutations, is of biological significance in the development of melanoma.
|
9036865 |
1997 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Morphometry, DNA content, and PCNA positivity thus seem to reflect different stages in tumor progression of malignant melanoma.
|
7864299 |
1994 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pools of PCNA in the cytoplasm, when transported into the nucleus, would support the rapid proliferation observed in melanomas.
|
7858412 |
1994 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PCNA (PC10) scores in the MCBN were significantly different from those in the CBN (P = .00003), MN (2.05%; P = .00001), and BN (5.06%; P = .00002), whereas they were not significantly different from those in the conventional MMs (28.9%; P = .49).
|
7903955 |
1993 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PCNA-positive cells in SN and MM were found both in dermal and junctional nests, while those in MN were found almost exclusively in the dermal nests.
|
8105711 |
1993 |